All In Biotech

NDA 022283 · Riley Consumer

Zegerid Otc

Omeprazole, Sodium Bicarbonate · Oral

Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jun 17, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

988

158 Phase 3, 48 recruiting

FAERS reports

339

294 serious, 29 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 17, 2013 Original approval · Type 8 - Partial Rx to OTC Switch LabelLetterReview
1 products under this application
  • ZEGERID OTC · OMEPRAZOLE 20MG/PACKET; SODIUM BICARBONATE 1.68GM/PACKET · FOR SUSPENSION, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.

All 988 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease224
  • acute kidney injury120
  • renal failure112
  • renal injury82
  • end stage renal disease65
  • tubulointerstitial nephritis38
  • gastrooesophageal reflux disease28
  • nephrogenic anaemia25
  • rebound acid hypersecretion25
  • nephropathy15
  • death13
  • renal impairment12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
201111
20126
20135
20146
20152
20169
201714
201846
2019153
202028
202123
20229
20239
20247
20253
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,390 on PubMed

Sponsor: Riley Consumer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.